Cardiology
From the Journals
PTSD symptoms in women tied to worse heart, brain health
Outcomes of interest were associations of PTSD symptoms with carotid intima media thickness, brain white matter hyperintensity volume, and...
Latest News
Bariatric surgery still best option for some with obesity
“Sometimes we might need to go straight to surgery instead of going through medications first, because it may be the most effective and evidence-...
From the Journals
Long-term use of ADHD meds and CVD risk: New data
“Clinicians should be vigilant in monitoring signs and symptoms of cardiovascular diseases, particularly among those receiving higher doses.”
Conference Coverage
‘Smart’ stethoscope spots peripartum cardiomyopathy
Finding that 4% of the women in the intervention arm had reduced ejection fraction is “absolutely startling ... and speaks to how important...
Latest News
At-home blood pressure monitoring is cost effective over long term
Home measurement appeared to be economical over a minimum 10-year period compared with usual care – higher expenditures for equipment and training...
Sponsored Supplement
An update on Aspirin for Cardioprevention
Latest News
FDA OKs symplicity renal denervation system for hypertension
The Symplicity Spyral system provides a catheter-based approach to denervate the renal arteries using radiofrequency energy.
Latest News
Single injection reduces blood pressure for 6 months: KARDIA-1
Zilebesiran is a subcutaneous RNA interference therapeutic that binds with high affinity to the hepatic asialoglycoprotein receptor, bringing...
Latest News
PREVENT: AHA’s new risk calculator incorporates CKM health
PREVENT is for use in adults aged 30-79 years and estimates the 10- and 30-year risk of total CVD including, for the first time, heart failure.
Feature
Revisiting the role of hydrocortisone, fludrocortisone in septic shock
Two decades after choosing not to treat septic shock with hydrocortisone and fludrocortisone, the author describes why he is reconsidering.
Commentary
A better way to control blood pressure
For the American medical-industrial complex, lowered costs for managing common serious diseases may be an undesired rather than a good thing.
Conference Coverage
Promising first results with DNA editing to lower LDL
The first in-human HEART-1 trial of in vivo DNA editing called VERVE-101, shows reductions in LDL and PCSK9 protein in patients with familial...